Begüm Işık

Begüm Işık

Auto-generated profile, based on publicly available information

Begüm Işık

Department of Dermatology Necmettin Erbakan University Meram Medical Faculty Konya Turkey

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2021 in Journal of Cosmetic Dermatology
Verified
Journal Article
Closed access
PDF file
STSelami Aykut Temiz
Selami Aykut Temiz
KDKoray Durmaz
Koray Durmaz
BIBegüm Işık
Begüm Işık
AAArzu Ataseven
Arzu Ataseven
RDRecep Dursun
Recep Dursun

23 December 2020 in Journal of Cosmetic Dermatology
Verified
Journal Article
Closed access
PDF file
MDMunise Daye
Munise Daye
STSelami Aykut Temiz
Selami Aykut Temiz
BIBegüm Isık
Begüm Isık

6 October 2020 in Dermatologic Therapy
Verified
Journal Article
Open access
PDF file
MDMunise Daye
Munise Daye
STSelami Aykut Temiz
Selami Aykut Temiz
BIBegüm Işık
Begüm Işık
RDRecep Dursun
Recep Dursun
AAArzu Ataseven
Arzu Ataseven
Disease‐related skin lesions have been reported in 8% to 20% of COVID‐19 patients. In the literature, cutaneous symptoms associated with the disease are generally emphasized. However, there are very few studies on the effect of this new SARS‐CoV‐2 virus entering our lives on dermatological diseases, and none of them have used the dermatological quality of life index (DLQI). In our study, we aimed to evaluate the difficulties faced by the patients who applied to the dermatology outpatient clinic during the pandemic period and the course of their diseases with the dermatological quality of life index. The study was carried out prospectively by including dermatology patients who will apply to the outpatient clinic in June‐July 2020. 282 patients were evaluated in the study. DLQI was significantly lower in the group using regular emollients (P < .001). When DLQI was compared between disease groups, it was found to be significantly different (P: .017). DLQI was found to worsen significantly compared to prepandemic studies. It was found that using moisturizer in this period helps to maintain the dermatological quality of life.

31 July 2021 in International Journal Of Clinical Practice
Verified
Journal Article
Closed access
PDF file
MDMunise Daye
Munise Daye
STSelami Aykut Temiz
Selami Aykut Temiz
BIBegüm Işık
Begüm Işık
YDYasemin Durduran
Yasemin Durduran

20 February 2022 in Journal of Cosmetic Dermatology
Verified
Journal Article
Closed access
PDF file
KDKoray Durmaz
Koray Durmaz
AAArzu Ataseven
Arzu Ataseven
STSelami Aykut Temiz
Selami Aykut Temiz
BIBegum Isik
Begum Isik
RDRecep Dursun
Recep Dursun

2 July 2024 in Cutaneous and Ocular Toxicology
Verified
Journal Article
Closed access
STSelami Aykut Temiz
Selami Aykut Temiz
RDRecep Dursun
Recep Dursun
SFSıddıka Fındık
Sıddıka Fındık
AAArzu Ataseven
Arzu Ataseven
BIBegüm Işık
Begüm Işık
İÖİlkay Özer
İlkay Özer
There is no marker that can predict whether there is resistance to treatment in patients with psoriasis. In this study, we investigated the relationship between the staining rates of TNF-α, IL-1, IL-12, IL-17, IL-23, and IL-36 markers immunohistochemically from cutaneous biopsy and the treatment success. The patients who were followed up in the dermatology clinic with the diagnosis of plaque-type psoriasis vulgaris and received biological treatment and previously had cutaneous biopsy were included in the study. The cutaneous biopsies of the cases that met the conditions were re-sectioned and subjected to immunohistochemical examination for TNF-α, IL-1, IL-12, IL-17, IL-23, and IL-36. Comparing the staining scores with psoriasis area severity index (PASI); A statistically significant positive correlation was found between PASI and TNF-α staining score(p = 0.034). A statistically significant positive correlation was found between PASI and IL-17 staining score(p = 0.004).When the staining scores and PASI response rates of psoriasis treatment were evaluated in terms of correlation; there was a positive correlation between TNF-α, IL-17, and IL-23 immunohistochemical staining rates and PASI response rates. In line with the data obtained from our study, we think that making immunohistochemical scoring before the biological treatment decision in psoriasis patients will be beneficial in treatment selection. In this respect, our study may open a new era in the selection of biological treatments for psoriasis.